Pharmacogenomics and Personalized Medicine Approaches

Pharmacogenomics studies how inherited genetic variation shapes a person's response to medicines, and personalized (or precision) medicine approaches use that information, together with other individual characteristics, to tailor therapy. The aim is to anticipate who is likely to benefit, who may not respond, and who is at elevated risk of harm.

Definition

Pharmacogenomics is the study of how variation across the genome influences drug response, and personalized medicine approaches are the use of such genetic information, alongside other patient factors, to individualize the selection and use of medicines.

Scope

This entry covers the principle that genetic variation in drug-metabolizing enzymes, transporters, and targets contributes to differences in drug response, and how curated evidence is translated into clinical guidance. It treats pharmacogenomics as a conceptual and methodological topic and does not provide genotype-specific dosing or treatment recommendations.

Core questions

• How does inherited genetic variation alter the way drugs are metabolized and act?
• Which gene-drug relationships have evidence strong enough to inform clinical use?
• How is pharmacogenomic knowledge curated, graded, and translated into guidance?
• How does genetic information combine with other patient factors in personalized therapy?

Key concepts

• Pharmacogenetics versus pharmacogenomics
• Drug-metabolizing enzyme polymorphism
• Metabolizer phenotype
• Gene-drug pairs
• Evidence curation and grading
• Genotype-guided therapy
• Precision medicine

Key theories

Genetic basis of drug-response variability

Inherited variation in genes encoding drug-metabolizing enzymes, transporters, and targets produces predictable differences in drug exposure and effect, providing a mechanistic basis for tailoring therapy to genotype.

Mechanisms

Genes encoding drug-metabolizing enzymes, transporters, and drug targets vary between individuals, and this variation can change how much active drug reaches its site of action and how strongly the target responds (Wang et al., 2011; Wilkinson, 2005). Variation in metabolizing enzymes can classify people into broad metabolizer categories that alter expected exposure for affected drugs. Translating these relationships into practice depends on curating the underlying evidence and grading its strength, work supported by knowledge bases such as PharmGKB and by structured evaluation frameworks (Whirl-Carrillo et al., 2012; Whirl-Carrillo et al., 2021), which in turn inform consortium guidelines for specific gene-drug pairs (Hicks et al., 2015).

Clinical relevance

Pharmacogenomics is increasingly part of clinical pharmacy, laboratory medicine, and therapeutics, where it informs how genetic information might refine drug selection and use. This entry explains the concepts and the evidence-translation process and is reference and educational material; it does not provide genotype-based dosing, drug selection, or treatment instructions for any individual.

Evidence & guidelines

Curated knowledge bases assemble and grade gene-drug evidence (Whirl-Carrillo et al., 2012), and structured frameworks formalize how that evidence is evaluated (Whirl-Carrillo et al., 2021). Bodies such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) publish gene-drug guidelines describing how, when a genotype is already known, it could inform therapy (Hicks et al., 2015). The specific, drug-level recommendations live in those guidelines and product labeling and are outside this reference entry.

History

Observations in the mid-twentieth century that some patients metabolized certain drugs unusually slowly or quickly seeded the field of pharmacogenetics. The completion of the human genome and advances in genotyping broadened it into pharmacogenomics, examining variation across the whole genome (Wang et al., 2011). Curated knowledge bases and grading frameworks then made the evidence usable (Whirl-Carrillo et al., 2012; Whirl-Carrillo et al., 2021), and implementation consortia began issuing gene-drug guidelines to support clinical translation (Hicks et al., 2015).

Debates

How and when should pre-emptive genotyping be used?

Testing a genotype before it is clinically needed could speed decisions later, but the value, cost, and equity of pre-emptive versus reactive testing, and which gene-drug pairs justify it, remain actively discussed as evidence accumulates.

Key figures

• Richard Weinshilboum
• Howard McLeod
• Teri Klein

Seminal works

• wang-2011
• whirl-carrillo-2012
• hicks-2015

Frequently asked questions

What is the difference between pharmacogenetics and pharmacogenomics?

Pharmacogenetics traditionally refers to how variation in one or a few genes affects response to a drug, while pharmacogenomics is the broader study of how variation across the whole genome influences drug response; the terms are often used interchangeably today.

Does a genetic test tell you exactly which drug or dose to use?

No. A genotype is one input among many; it may indicate that a person falls into a metabolizer category relevant to certain drugs, but selection and dosing also depend on clinical context, other patient factors, and current clinical guidance.